tiprankstipranks
Trending News
More News >
Ascentage Pharma Group International Unsponsored ADR (AAPG)
NASDAQ:AAPG
US Market

Ascentage Pharma Group International Unsponsored ADR (AAPG) Stock Forecast & Price Target

Compare
22 Followers
See the Price Targets and Ratings of:

AAPG Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Ascentage
Pharma Group International Unsponsored ADR
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AAPG Stock 12 Month Forecast

Average Price Target

$48.80
▲(75.04% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Ascentage Pharma Group International Unsponsored ADR in the last 3 months. The average price target is $48.80 with a high forecast of $51.00 and a low forecast of $45.00. The average price target represents a 75.04% change from the last price of $27.88.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","25":"$25","34":"$34","43":"$43","52":"$52"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,25,34,43,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.46,34.80923076923077,36.15846153846154,37.50769230769231,38.85692307692308,40.206153846153846,41.55538461538462,42.90461538461538,44.253846153846155,45.60307692307693,46.95230769230769,48.30153846153846,49.65076923076923,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.46,34.64,35.82,37,38.18,39.36,40.54,41.72,42.9,44.08,45.26,46.44,47.62,{"y":48.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.46,34.347692307692306,35.23538461538462,36.12307692307692,37.010769230769235,37.89846153846154,38.786153846153844,39.673846153846156,40.56153846153846,41.449230769230766,42.33692307692308,43.22461538461538,44.112307692307695,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.25,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.68,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.03,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$51.00Average Price Target$48.80Lowest Price Target$45.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Lucid Capital Analyst forecast on AAPG
Lucid Capital
Lucid Capital
$50
Buy
79.34%
Upside
Initiated
12/15/25
Ascentage Pharma initiated with a Buy at Lucid CapitalAscentage Pharma initiated with a Buy at Lucid Capital
Piper Sandler Analyst forecast on AAPG
Piper Sandler
Piper Sandler
$48
Buy
72.17%
Upside
Reiterated
12/12/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM), Kestra Medical Technologies Ltd. (NASDAQ: KMTS) and Ascentage Pharma Group International Unsponsored ADR (NASDAQ: AAPG)
Oppenheimer Analyst forecast on AAPG
Oppenheimer
Oppenheimer
$45
Buy
61.41%
Upside
Initiated
12/04/25
Ascentage Pharma initiated with an Outperform at OppenheimerAscentage Pharma initiated with an Outperform at Oppenheimer
BTIG
$50
Buy
79.34%
Upside
Reiterated
12/02/25
BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)
Truist Financial Analyst forecast on AAPG
Truist Financial
Truist Financial
$51
Buy
82.93%
Upside
Initiated
11/24/25
Ascentage Pharma Group International Unsponsored ADR (AAPG) Initiated with a Buy at Truist Financial
J.P. Morgan Analyst forecast on AAPG
J.P. Morgan
J.P. Morgan
$46$47
Buy
68.58%
Upside
Reiterated
09/02/25
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), Ascentage Pharma Group International Unsponsored ADR (AAPG)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Lucid Capital Analyst forecast on AAPG
Lucid Capital
Lucid Capital
$50
Buy
79.34%
Upside
Initiated
12/15/25
Ascentage Pharma initiated with a Buy at Lucid CapitalAscentage Pharma initiated with a Buy at Lucid Capital
Piper Sandler Analyst forecast on AAPG
Piper Sandler
Piper Sandler
$48
Buy
72.17%
Upside
Reiterated
12/12/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM), Kestra Medical Technologies Ltd. (NASDAQ: KMTS) and Ascentage Pharma Group International Unsponsored ADR (NASDAQ: AAPG)
Oppenheimer Analyst forecast on AAPG
Oppenheimer
Oppenheimer
$45
Buy
61.41%
Upside
Initiated
12/04/25
Ascentage Pharma initiated with an Outperform at OppenheimerAscentage Pharma initiated with an Outperform at Oppenheimer
BTIG
$50
Buy
79.34%
Upside
Reiterated
12/02/25
BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)
Truist Financial Analyst forecast on AAPG
Truist Financial
Truist Financial
$51
Buy
82.93%
Upside
Initiated
11/24/25
Ascentage Pharma Group International Unsponsored ADR (AAPG) Initiated with a Buy at Truist Financial
J.P. Morgan Analyst forecast on AAPG
J.P. Morgan
J.P. Morgan
$46$47
Buy
68.58%
Upside
Reiterated
09/02/25
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), Ascentage Pharma Group International Unsponsored ADR (AAPG)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascentage Pharma Group International Unsponsored ADR

1 Month
xxx
Success Rate
2/4 ratings generated profit
50%
Average Return
+6.22%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +6.22% per trade.
3 Months
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
+8.72%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of +8.72% per trade.
1 Year
Brian ChengJ.P. Morgan
Success Rate
1/4 ratings generated profit
25%
Average Return
-10.38%
reiterated a buy rating 4 months ago
Copying Brian Cheng's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -10.38% per trade.
2 Years
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-10.38%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -10.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AAPG Analyst Recommendation Trends

Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
2
6
Buy
3
4
3
2
2
Hold
3
0
0
0
0
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
6
4
4
5
9
In the current month, AAPG has received 8 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. AAPG average Analyst price target in the past 3 months is 48.80.
Each month's total comprises the sum of three months' worth of ratings.

AAPG Financial Forecast

AAPG Earnings Forecast

Next quarter’s earnings estimate for AAPG is -$0.42 with a range of -$0.42 to -$0.42. The previous quarter’s EPS was -$0.97. AAPG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AAPG has Performed in-line its overall industry.
Next quarter’s earnings estimate for AAPG is -$0.42 with a range of -$0.42 to -$0.42. The previous quarter’s EPS was -$0.97. AAPG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AAPG has Performed in-line its overall industry.

AAPG Sales Forecast

Next quarter’s sales forecast for AAPG is $20.00M with a range of $20.00M to $20.00M. The previous quarter’s sales results were $32.21M. AAPG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AAPG has Performed in-line its overall industry.
Next quarter’s sales forecast for AAPG is $20.00M with a range of $20.00M to $20.00M. The previous quarter’s sales results were $32.21M. AAPG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AAPG has Performed in-line its overall industry.

AAPG Stock Forecast FAQ

What is AAPG’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascentage Pharma Group International Unsponsored ADR’s 12-month average price target is 48.80.
    What is AAPG’s upside potential, based on the analysts’ average price target?
    Ascentage Pharma Group International Unsponsored ADR has 75.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AAPG a Buy, Sell or Hold?
          Ascentage Pharma Group International Unsponsored ADR has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ascentage Pharma Group International Unsponsored ADR’s price target?
            The average price target for Ascentage Pharma Group International Unsponsored ADR is 48.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $51.00 ,the lowest forecast is $45.00. The average price target represents 75.04% Increase from the current price of $27.88.
              What do analysts say about Ascentage Pharma Group International Unsponsored ADR?
              Ascentage Pharma Group International Unsponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of AAPG?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.